Advertisement

Prostate Cancer and Radical Treatment

  • Sanchia S. Goonewardene
  • Raj Persad
Chapter

Abstract

The most common histological type of prostate cancer is adenocarcinoma (cancer cells arising from glandular tissue). Active curative treatment for patients diagnosed with prostate cancer, include radiotherapy (radiation directed at the prostate) or brachytherapy (insertion of radioactive seeds into the prostate gland) or radical surgery (surgical removal of the prostate gland and surrounding lymph nodes). Surgery can be conducted as an ‘open’ procedure, with cameras (laparoscopic) or using a robot (robotically). For the purposes of this book, the focus is on men post radical robotic surgery for prostate cancer.

References

  1. 1.
    Dasgupta P, Jones A, Gill IS. Robotic urological surgery: a perspective. BJU Int Suppl. 2005;95:20–3.CrossRefGoogle Scholar
  2. 2.
    Barnett C, Kumar P, Challacombe B, Dasgupta P. Robot assisted laparoscopic prostatectomy. Striving for Trifecta outcomes in localised prostate cancer. Minerva Med. 2011;102:333–8.Google Scholar
  3. 3.
    McCammon KA, Kolm P, Main B, Schellhammer PF. Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology. 1999;54:509–16.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Briganti A, Capitanio U, Chun FKH, Karakiewicz PI, Salonia A, Bianchi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Prediction of sexual function after radical prostatectomy. Cancer. 2009;115:3150–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Briganti A, Salonia A, Zanni G, Fabbri F, Sacca A, Bertini R, Suardi N, Fantini GV, Rigatti P, Montorsi F. Erectile dysfunction and radical prostatectomy: an update. EAU Update Ser. 2004;2:84–92.CrossRefGoogle Scholar
  6. 6.
    D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bober SL, Sanchez Varela V. Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol. 2012;30:3712–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Flynn KE, Jeffery DD, Keefe FJ, Porter LS, Shelby RA, Fawzy MR, Gosselin TK, Reeve BB, Weinfurt KP. Sexual functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS). Psychooncology. 2011;20:378–86.CrossRefGoogle Scholar
  9. 9.
    D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Tomaszewski JE, Wein A. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol. 1998;160:2096–101.CrossRefGoogle Scholar
  10. 10.
    Akbal C, Tinay I, Simsek F, Turkeri LN. Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment. Int Urol Nephrol. 2008;40:355–63.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
  • Raj Persad
    • 2
  1. 1.The Royal Free Hospital and UCLLondonUnited Kingdom
  2. 2.North Bristol NHS TrustBristolUnited Kingdom

Personalised recommendations